Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel
2008

Complement Factor H Gene Variant and Age-Related Macular Degeneration in Israel

Sample size: 240 publication Evidence: moderate

Author Information

Author(s): Itay Chowers, Yoram Cohen, Nitza Goldenberg-Cohen, Joaquin Vicuna-Kojchen, Alejandro Lichtinger, Orly Weinstein, Ayala Pollack, Ruth Axer-Siegel, Itzhak Hemo, Edward Averbukh, Eyal Banin, Tal Meir, Michal Lederman

Primary Institution: Hadassah–Hebrew University Medical Center

Hypothesis

Is the Tyr402His variant of complement factor H associated with age-related macular degeneration in the Israeli population?

Conclusion

The Tyr402His variant of CFH is associated with neovascular age-related macular degeneration in Israel, but does not explain variations in clinical manifestations or responses to treatment.

Supporting Evidence

  • The Tyr402His variant was associated with NVAMD with an odds ratio of 1.9.
  • Homozygosity for this variant had an odds ratio of 3.4 for having AMD.
  • No association was found between the SNP and age of onset, gender, or visual acuity.

Takeaway

A specific gene variant is linked to a type of eye disease in people from Israel, but it doesn't explain why some people have different symptoms or respond differently to treatments.

Methodology

Genotyping for the Tyr402His variant was performed in 240 NVAMD patients and 118 controls, with correlations made to clinical characteristics and treatment parameters.

Potential Biases

Potential bias due to the unequal representation of ethnic groups in the study sample.

Limitations

The study had a limited number of Arab participants, which may affect the generalizability of the findings.

Participant Demographics

240 NVAMD patients (mean age 78.1) and 118 controls (mean age 70.8), including Arabs, Sephardic Jews, and Ashkenazi Jews.

Statistical Information

P-Value

0.0002

Confidence Interval

95% CI=1.3–2.6

Statistical Significance

p=0.0002

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication